Showing results (251-260 of 302) with videos related to

Sort By:
Pageof 31
The American Journal of Psychiatry|April 6, 2006
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychoticT Scott Stroup, Jeffrey A Lieberman, Joseph P McEvoy, et al.
The American Journal of Psychiatry|March 3, 2007
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE studyT Scott Stroup, Jeffrey A Lieberman, Joseph P McEvoy, et al.
Journal of Psychiatric Research|April 16, 2022
25-Hydroxyvitamin D and metabolic-related laboratory values in women with schizophrenia and hyperprolactinemiaMadhulika C Nallani, Megan M Powell, Sharon Pugh, et al.
The Psychiatric Quarterly|May 4, 2017
Adjunctive Minocycline in Clozapine-Treated Patients with Schizophrenia: Analyzing the Effects of Minocycline on Clozapine Plasma LevelsHeidi J Wehring, Teresa Elsobky, Joseph P McEvoy, et al.
Pharmacological Research|February 3, 2005
Identification of a naturally occurring 21 bp deletion in alpha 2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatmentVincenzo De Luca, John B Vincent, Daniel J Müller, et al.
Schizophrenia Research|September 21, 2005
Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trialDel D Miller, Joseph P McEvoy, Sonia M Davis, et al.
The British Journal of Psychiatry : the Journal of Mental Science|December 2, 2005
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidolRobert B Zipursky, Hongbin Gu, Alan I Green, et al.
The American Journal of Psychiatry|March 3, 2007
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE studyMarvin S Swartz, Diana O Perkins, T Scott Stroup, et al.
Neuroscience Letters|April 13, 2005
The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophreniaDaniel J Müller, Tim A Klempan, Vincenzo De Luca, et al.
Schizophrenia Research|February 9, 2008
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1Jonathan M Meyer, Vicki G Davis, Donald C Goff, et al.
Pageof 31